Ras/Raf signalling and emerging pharmacotherapeutic targets

Bibliography

• VIRCHOW R: Die Cellularpathologie. (1858)
   Google Scholar
• PEARSON G, ROBINSON F, BEERS GT et al.: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev (2001) 22:153–183.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review on the regulationand function of MAPK pathways.
   Google Scholar
• LEWIS TS, SHAPIRO PS, AHN NG: Signal transduction through MAPK cascades. Adv. Cancer Res. (1998) 74:49–139.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review on the regulationand function of MAPK pathways with focus on the different substrates of MAPKs.
   Google Scholar
• EBINU JO, BOTTORFF DA, CHAN EY,STANG SL, DUNN RJ, STONE JC: RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Science (1998) 280:1082–1086.
   PubMed Web of Science ®Google Scholar
• DHILLON AS, MEIKLE S, YAZICI Z, EULITZ M, KOLCH W: Regulation of Raf-1 activation and signalling by dephos-phorylation. EMBO J. (2002) 21:64–71.
   PubMed Web of Science ®Google Scholar
• KOLCH W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. (2000) 351:289–305.
   Google Scholar
• ••Comprehensive review of the regulation ofthe Ras-Raf-MEK-ERK pathway with emphasis on the role of protein:protein interactions, scaffolds and docking sites.
   Google Scholar
• AVRUCH J, KHOKHLATCHEV A, KYRIAKIS JM et al.: Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAPK cascade. Recent Prog. Dorm. Res. (2001) 56:127–55.
   PubMedGoogle Scholar
• ••Review focusing on the regulation of theERK pathway though Ras proteins.
   Google Scholar
• MARSHALL CJ: Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation. Cell (1995) 80:179–185.
   PubMed Web of Science ®Google Scholar
• •Review of the role of activation strength and kinetics of ERK for the biological outcome.
   Google Scholar
• LLOYD AC, OBERMULLER F, STADDON S, BARTH CE MCMAHON M, LAND H: Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. (1997) 11:663–677.
   PubMedGoogle Scholar
• ••First in a series of papers describing thathigh intensity Raf signalling arrests the cell cycle through induction of the p21CIP/ WAF cell cycle inhibitor.
   Google Scholar
• MURAKAMI MS, MORRISON DK: Raf-1 without MEK? Sci. STKE (2001) 2001:E30
   Google Scholar
• HOUSLAY MD, KOLCH W: Cell type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signalling. Ma Pharmacol (2000) 58:659–668.
   PubMedGoogle Scholar
• HINDLEY A, KOLCH W: Extracellular signal Regulated Kinase (ERK)/Mitogen Activated Protein Kinase (MAPK) independent functions of Raf kinases. J. Cell Sci. (2002) 115:1575–1581.
   PubMed Web of Science ®Google Scholar
• MIKULA M, SCHREIBER M, HUSAK Z et al.: Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO (2001) 20:1952–62.
   PubMed Web of Science ®Google Scholar
• •These two references describe the phenotype of Raf-1 knockout mice suggesting that Raf-1 has functions independent of the ERK pathway, probably in the regulation of apoptosis.
   Google Scholar
• HUSER M, LUCKETT J, CHILOECHES A et al.: MEK kinase activity is not necessary for Raf-1 function. EMBO (2001) 20:1940–51.
   PubMed Web of Science ®Google Scholar
• •These two references describe the phenotype of Raf-1 knockout mice suggesting that Raf-1 has functions independent of the ERK pathway, probably in the regulation of apoptosis.
   Google Scholar
• PEARSON G, BUMEISTER R, HENRY DO, COBB MH, WHITE MA: Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation. Biol. Chem. (2000) 275:37303–37306.
   Google Scholar
• MONTES M, TAGIEVA NE, HEVEKER N, NAHMIAS C, BALEUX F, TRAUTMANN A: SDF-1-induced activation of ERK enhances HIV-1 expression. Eur. Cytokine Netw. (2000) 11:470–477.
   PubMedGoogle Scholar
• PLESCHKA S, WOLFF T, EHRHARDT C, HOBOM G, PLANZ O, RAPP UR, LUDWIG S: Influenza virus propagation is impaired by inhibition of the Raf/MEK/ ERK signalling cascade. Nat. Cell Biol. (2001) 3:301–305.
   PubMed Web of Science ®Google Scholar
• RAPOPORT M, FERREIRA A: PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J. Neurochem. (2000) 74:125–133.
   PubMed Web of Science ®Google Scholar
• ZUBKOV AY, TIBBS RE, AOKI K, ZHANG JH: Prevention of vasospasm in penetrating arteries with MAPK inhibitors in dog double-hemorrhage model. Surg. Neural. (2000) 54:221–227.
   PubMedGoogle Scholar
• CLERK A, SUGDEN PH: Activation of protein kinase cascades in the heart by hypertropic G protein-coupled receptor agonists. Am.j Cardiol (1999) 83:64H–69H.
   Google Scholar
• HOSHINO R, CHATANI Y, YAMORI T et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signalling pathway in human tumours. Oncogene (1999) 18:813–822.
   PubMed Web of Science ®Google Scholar
• •Survey of cancer cell lines showing that the ERK pathway is activated in - 30% of all cancer cell lines. ERK activation is particularly frequent in lines derived from pancreas, colon, lung, ovary and kidney cancers.
   Google Scholar
• ADJEI AA: Blocking oncogenic Ras signalling for cancer therapy. J. Natl. Cancer Inst. (2001) 93:1062–1074.
   PubMed Web of Science ®Google Scholar
• GIBBS RA, ZAHN TJ, SEBOLT-LEOPOLD JS: Nonpeptidic prenyltransferase inhibitors: diverse structural classes and surprising anticancer mechanisms. Curt: Med. Chem. (2001) 8:1437–1465.
   PubMedGoogle Scholar
• SEBTI SM, HAMILTON AD: Farnesyltransferase and geranyl-geranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene (2000) 19:6584–6593.
   PubMed Web of Science ®Google Scholar
• WHYTE DB, KIRSCHMEIER P, HOCKENBERRY TN et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. (1997) 272:14459–14464.
   PubMed Web of Science ®Google Scholar
• LOBELL RB, OMER CA, ABRAMS MT et al: Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. (2001) 61:8758–8768.
   PubMed Web of Science ®Google Scholar
• SUN J, QIAN Y, HAMILTON AD, SEBTISM: Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumour growth in nude mouse xenografts. Oncogene (1998) 16:1467–1473.
   PubMed Web of Science ®Google Scholar
• PRENDERGAST GC, PANE N: Farnesyltransferase inhibitors: mechanism and applications. Expert. Opin. Investig. Drugs (2001) 10:2105–2116.
   PubMed Web of Science ®Google Scholar
• •A review focusing on the mechanistic aspects of FT inhibitors and their potential application to non-neoplastic diseases.
   Google Scholar
• KARP JE, KAUFMANN SH, ADJEI AA, LANCET JE, WRIGHT JJ, END DW: Current status of clinical trials of farnesyltransferase inhibitors. Curt: Opin. Oncol (2001) 13:470–476.
   PubMed Web of Science ®Google Scholar
• ••A current review of clinical trials of Rasisoprenylation inhibitors in cancers and leukaemias. The mechanisms, efficacy as single agents and in combination with cytotoxic drugs is reviewed.
   Google Scholar
• SUN J, BLASKOVICH MA, KNOWLES D et al: Antitumour efficacy of a novel class of nonthiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol and gemcitabine. Cancer Res. (1999) 59:4919–4926.
   PubMed Web of Science ®Google Scholar
• ••A meticulous dissection of the efficacies ofFT and GGT inhibitors in a nude mouse tumour model as monotherapies and in combination therapy with established chemotherapeutic drugs showing that combination therapy is superior.
   Google Scholar
• FLAHERTY KT, STEVENSON JP, O'DWYER PJ: Antisense therapeutics: lessons from early clinical trials. Carr. Opin. Oncol (2001) 13:499–505.
   PubMedGoogle Scholar
• CUNNINGHAM CC, HOLMLUND JT, GEARY RS et al.: A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer (2001) 92:1265–1271.
   PubMed Web of Science ®Google Scholar
• KASHANI-SABET M, FUNATO T, FLORENES VA, FODSTAD O, SCANLON KJ: Suppression of the neoplastic phenotype in vivo by an antiras ribozyme. Cancer Res. (1994) 54:900–902.
   PubMed Web of Science ®Google Scholar
• SCHERR M, GREZ M, GANSER A, ENGELS JW: Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA M vitro and ex vivo. Oligoribonucleotides as therapeutic agents. Biol Chem. (1997) 272:14304–14313.
   Google Scholar
• ZHANG YA, NEMUNAITIS J, SCANLON KJ, TONG AW: Antitumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Thec (2000) 7:2041–2050.
   PubMed Web of Science ®Google Scholar
• KHLEIF SN, ABRAMS SI, HAMILTON JM et al: A Phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumours.' Immunothec (1999) 22:155–165.
   PubMed Web of Science ®Google Scholar
• CORBETT KD, ALBERT: The many faces of Ras: recognition of small GTP-binding proteins. Trends Biochem. Sci. (2001) 26:710–716.
   PubMedGoogle Scholar
• •A comprehensive review on the structural basis of Ras interaction with effectors.
   Google Scholar
• HERRMANN C, BLOCK C, GEISEN C et al.: Sulindac sulfide inhibits Ras signalling. Oncogene (1998) 17:1769–1776.
   PubMed Web of Science ®Google Scholar
• ••First report of a nonpeptidomirnetic, lowmolecular weight compound that disrupts the Ras/Raf-1 protein interaction and inhibits GDP/GTP exchange. The active metabolite is sulindac sulfide, which is proposed to serve as a lead substance.
   Google Scholar
• KARAGUNI IM, GLU-SENKAMP KH, LANGERAK A et al.: New indene-derivatives with antiproliferative properties. Bioorg. Med. Chem. Lett. (2002) 12:709–713.
   PubMedGoogle Scholar
• •Based on the work of [38], sulindac derivatives are synthesised and structural determinants of improved efficacy are discussed.
   Google Scholar
• FRIESE A, HELL-MOMENI K, ZUNDORF I, WINCKLER T, DINGERMANN T, DANNHARDT G: Synthesis and biological evaluation of cycloalkylidene carboxylic acids as novel effectors of ras/raf interaction. I Med. Chem. (2002) 45:1535–1542.
   PubMedGoogle Scholar
• •This paper describes a class of low molecular weight compounds that are notable in two ways. They were found using yeast as drug screening system and they stabilise the Ras/Raf-1 interaction.
   Google Scholar
• CLARK GJ, DRUGAN JK, TERRELL RS et al.: Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function. Proc. Natl. Acad. Sci. USA (1996) 93:1577–1581.
   PubMed Web of Science ®Google Scholar
• HORN IR, WITTINGHOFER A, DE BRUINE AP, HOOGENBOOM HR: Selection of phage-displayed fab antibodies on the active conformation of ras yields a high affinity conformation-specific antibody preventing the binding of c-Raf kinase to Ras. FEBS Lett. (1999) 463:115–120.
   PubMedGoogle Scholar
• KIMOTO M, SHIROUZU M, MIZUTANI S et al: Anti(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation. Eut: Biochem. (2002) 269:697–704.
   PubMedGoogle Scholar
• •Description of new improved RNA aptamers that can differentiate between Raf-1 and B-Raf activation.
   Google Scholar
• COFFEY MC, STRONG JE, FORSYTH PA, LEE PW: Reovirus therapy of tumours with activated Ras pathway. Science (1998) 282:1332–1334.
   PubMed Web of Science ®Google Scholar
• •The observation that reovirus needs an activated Ras pathway for replication is exploited to selectively lyse Ras-dependent tumour cells. An elegant example how basic science can be turned into an exciting application.
   Google Scholar
• NORMAN KL, COFFEY MC, HIRASAWA K et al.: Reovirus oncolysis of human breast cancer. Hum. Gene Thec (2002) 13:641–652.
   PubMed Web of Science ®Google Scholar
• GROMEIER M: Viruses as therapeutic agents against malignant disease of the central nervous system. Natl. Cancer Inst. (2001) 93:889–890.
   Google Scholar
• KOLCH W, KOTWALIWALE A, VASS K, JANOSCH P: The role of Raf kinases in malignant transformation. Expert Rev Ma Med. (2002). In press. Available from www.expertreviews.org/02004386h.htm.
   Google Scholar
• WEINSTEIN-OPPENHEIMER CR, BLALOCK WL, STEELMAN LS, CHANG F, MCCUBREY JA: The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumours. Pharmacol Thec (2000) 88:229–79.
   PubMedGoogle Scholar
• ••A comprehensive overview of the availabledrugs targeting the ERK pathway. It contains an extensive discussion of drugs targeting receptors.
   Google Scholar
• HALL-JACKSON CA, EYERS PA, COHEN P et al.: Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. (1999) 6:559–568.
   PubMed Web of Science ®Google Scholar
• WOOD E, CROSBY RIVI, DICKERSON S et al.: A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity. Anti-Cancer Drug Des. (2001) 16:1–6.
   PubMedGoogle Scholar
• HEIMBROOK DC, HUBER HE, STIRDIVANT SM et al.: Identification of potent, selective inhibitors of Raf. Proc. Amer. Assoc. Cancer Res. (1998) 39:3793–3793.
   Google Scholar
• LYONS JF, WILHELM S, HIBNER B, BOLLAG G: Discovery of a novel Raf kinase inhibitor. Endocc Relat. Cancer (2001) 8:219–225.
   PubMed Web of Science ®Google Scholar
• RUDIN CM, HOLMLUND J, FLEMING GF et al: Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf 1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. (2001) 7:1214–1220.
   PubMed Web of Science ®Google Scholar
• HOLMLUND JT, MONIA BP, KWOH TJ, DORR FA: Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Can: Opin. Mol. Ther: (1999) 1:372–385.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of antisense oligonudeotides in clinical cancer trials.
   Google Scholar
• SCHUMACHER C, CIOFFI CL, SHARIF H, HASTON W, MONIA BP, WENNOGLE L: Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications. Mol. Pharmacol. (1998) 53:97–104.
   PubMedGoogle Scholar
• STEPKOWSKI SM, QU X, WANG ME et al.: Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats. Transplantation (2000) 70:656–661.
   PubMedGoogle Scholar
• WORKMAN P, MALONEY A: HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther: (2002) 2:3–24.
   Google Scholar
• •A review of the mechanism and therapeutical potential of geldanarnycin and derivative drugs that inhibit the chaperone function of HSP90.
   Google Scholar
• PIEKARZ RL, ROBEY R, SAND OR Vetal.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T cell lymphoma: a case report. Blood (2001) 98:2865–2868.
   Google Scholar
• ALESSI DR, CUENDA A, COHENP, DUDLEY DT, SALTIEL AR: PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. (1995) 270:27489–27494.
   PubMed Web of Science ®Google Scholar
• •A thorough biochemical study of the first MEK inhibitor.
   Google Scholar
• FAVATA ME HORIUCHI KY, MANOS EJ et al.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. (1998) 273:18623–18632.
   PubMedGoogle Scholar
• SEBOLT-LEOPOLD JS, DUDLEY DT, HERRERA R et al: Blockade of the MAPK pathway suppresses growth of colon tumours in vivo. Nat. Med. (1999) 5:810–816.
   PubMed Web of Science ®Google Scholar
• ••First direct proof that the ERK pathway isa valid target for cancer therapy. Also the first report of orally available MEK inhibitors.
   Google Scholar
• VAN BECELAERE K, VALIK H, PRZYBRANOWSKI S etal.: Determinants of sensitivity to MAPK pathway intervention by MEK inhibition. Proc. Amer. Assoc. Cancer Res. (2001) 42:4953–4953.
   Google Scholar
• MODY N, LEITCH J, ARMSTRONG C, DIXON J, COHEN P: Effects of MAPK cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. (2001) 502:21–24.
   PubMed Web of Science ®Google Scholar
• ZHANG N, WU B, POWELL D et al.: Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:2825–2828.
   PubMedGoogle Scholar
• ZHAO A, LEE SH, MOJENA M et al.: Resorcylic acid lactones: naturally-occurring potent and selective inhibitors of MEK. Antibior (Tokyo) (1999) 52:1086–1094.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DH, WILKINSON SE, PURTON T, LAMONT A, FLOTOW H, MURRAY EJ: Ro 09-2210 exhibits potent antiproliferative effects on activated T cells by selectively blocking MKK activity. Biochemistry (1998) 37:9579–9585.
   PubMed Web of Science ®Google Scholar
• YEUNG K, SEITZ T, LI S et al.: Suppression of Raf-1 kinase activity and MAPK signalling by RKIP. Nature (1999) 401:173–177.
   PubMed Web of Science ®Google Scholar
• •A physiological protein inhibitor of the ERK pathway is described that prevents MEK activation by disrupting the interaction between Raf and MEK.
   Google Scholar
• GAY B, SUAREZ S, CARAVATTI G, FURET P, MEYER T, SCHOEPFER J: Selective Grb2 5H2 inhibitors as antiRas therapy. Int. J. Cancer (1999) 83:235–241.
   PubMed Web of Science ®Google Scholar
• •Description of an inhibitor of protein:protein interactions that has been obtained by rational drug design.
   Google Scholar
• DUESBERY NS, RESAU J, WEBB CP et al.: Suppression of Ras-mediated transformation and inhibition of tumour growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc. Nati Acad. Sci. USA (2001) 98:4089–4094.
   PubMed Web of Science ®Google Scholar
• •Anthrax lethal toxin inhibits several MAPK pathways by proteolytic removal of MAPK docking domains from MAPKKs. This report validates the use of this principle for cancer therapy.
   Google Scholar
• BRUNET A, ROUX D, LENORMAND P, DOWD S, KEYSE S, POUYSSEGUR J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. (1999) 18:664–674.
   PubMed Web of Science ®Google Scholar
• CHOW S, PATEL H, HEDLEY DW: Measurement of MAPK activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry (2001) 46:72–78.
   PubMedGoogle Scholar